Alpha Paradigm Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Alpha Paradigm Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$72K	Buy	+302	New	+$64.4K	0.03%	401

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alpha Paradigm Partners's ALNY Position: Q4 2022 in Review

Alpha Paradigm Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2022: 302 shares worth $72K. The stake represents 0.03% of the portfolio and ranks #401 among its holdings.

487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

Alpha Paradigm Partners held 302 shares of Alnylam Pharmaceuticals worth $72K as of Q4 2022.
Alnylam Pharmaceuticals was a new Alpha Paradigm Partners position in Q4 2022.
Alnylam Pharmaceuticals made up 0.03% of Alpha Paradigm Partners's portfolio in Q4 2022, its #401 holding.
487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.